Thomson Reuters Foundation

Inform - Connect - Empower

Oxfam calls on EU not to shut down ?pharmacy of the developing world?

Oxfam GB - UK - Thu, 9 Feb 2012 12:35 GMT
Author: Oxfam
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

Any views expressed in this article are those of the author and not of Thomson Reuters Foundation.

On the eve of a high-level summit between the leaders of India and the European Union in Delhi, Oxfam is calling on the EU not to pressurise India into agreeing new trade rules that could deny hundreds of millions of people access to affordable medicines. The negotiations, which have been on-going for four years, are a means for the two economies to agree on a trade pact and forge a new commercial relationship. The EU, backed by multinational pharmaceutical companies, are trying to impose new intellectual property and investment (IP) rules in India, which would result in drastically higher medicine prices for the poorest people across the globe. Oxfam policy advisor, Rohit Malpani, said. "The summit on Friday will be closely watched to see whether the EU and India will negotiate a trade agreement which puts people's lives before the commercial interests of multinational drug companies. "At a time of austerity and declining aid budgets, especially for health, efforts to increase medicine prices for the world's poor would be a double blow and have a devastating impact on the achievement of health-related Millennium Development Goals."� India plays a critical role in the global medicines market, producing over two-thirds of all generic medicines; affordable versions of drugs licensed by multinational companies, which are largely sold to poor and middle income countries. Currently, over 80 per cent of all HIV and AIDS medicines are manufactured by generic companies in India, but if new trade rules are agreed the price of life-saving treatment would increase drastically*. Oxfam India CEO, Nisha Agrawal, said. "The Indian Government - until now - has repeatedly rejected the EU demands to introduce any of the additional intellectual property rules under the free trade agreement.� We strongly support that stance.�Given the background of ongoing policy level discussions on universal, affordable and free access to health care in India, to introduce additional intellectual property rules as a condition of the free trade agreement would be contradictory, since it would escalate the cost of medicines in India and also across the developing world." Malpani added. "If the EU succeeds in imposing strict IP rules upon the Indian Government, the massive hike in medicine prices could undermine European leadership to provide international aid for global health. Worryingly it could also debilitate donor programmes that provide access to treatment around the world." /Ends For more information, or to arrange an interview with an Oxfam spokesperson, please contact: Sarah Dransfield on +44(0)1865 472269, +44 (0)7767 085636 or Notes to editors:An Oxfam media briefing for the EU-India Summit, Affordable Medicines under Threat, is available. � *the cost of medicines drops 90-99 percent with generic competition. Delays in introducing generics will result in medicine prices remaining patented and too expensive - which will increase the cost of health care for governments and households. More from the Oxfam Press Office at

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular

Latest slideshow

See allSee all
Featured jobs